Live Feeds
● TRACKER Updated 11d ago · 50 sources tracked

GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients

Lawsuits claim diabetes and weight-loss treatments Ozempic, Wegovy, Mounjaro, and Zepbound caused permanent blindness linked to NAION. As of October 1, 2026, 247 vision-loss cases are pending in federal court. The legal actions are proceeding in two separate multidistrict litigations in Pennsylvania. No settlements have been reported yet.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (50)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ 247 vision-loss cases are pending in federal court as of October 1, 2026.
  • ✓ The legal actions are proceeding in two separate multidistrict litigations in Pennsylvania.
  • ✓ No settlements have been reported yet.
  • ✓ The lawsuits claim that Ozempic, Wegovy, Mounjaro, and Zepbound caused permanent blindness linked to a rare optic nerve condition known as NAION.
🛡️ Source Corroboration: 50 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

The number of pending vision-loss cases has been updated to 247 as of October 1, 2026.

Live updates

  1. Lawsuits against Novo, Eli Lilly over vision loss in patients

    Lawsuits claim diabetes and weight-loss treatments Ozempic, Wegovy, Mounjaro, and Zepbound caused permanent blindness linked to NAION. As of October 1, 2026, 247 vision-loss cases are pending in federal court. The legal actions are proceeding in two separate multidistrict litigations in Pennsylvania. No settlements have been reported yet.

    Why it matters

    These lawsuits involve medications from Novo Nordisk and Eli Lilly, which are used to treat type 2 diabetes and obesity. The plaintiffs claim that these medications led to a rare optic nerve condition known as NAION, resulting in sudden and permanent vision loss. The cases are being consolidated in multidistrict litigations to streamline the legal process.

    What is confirmed

    • 247 vision-loss cases are pending in federal court as of October 1, 2026.
    • The legal actions are proceeding in two separate multidistrict litigations in Pennsylvania.
    • No settlements have been reported yet.
    • The lawsuits claim that Ozempic, Wegovy, Mounjaro, and Zepbound caused permanent blindness linked to a rare optic nerve condition known as NAION.

    What to watch next

    • Further updates on the number of pending cases
    • Any potential settlements or rulings in the multidistrict litigations
    • New evidence or research on the link between GLP-1 medications and NAION
    Sources used for this update (4)
    1. lawfold.com — GLP Lawsuit (Updated October 2026) - lawfold.com
    2. medshadow.org — GLP-1 Lawsuits Raise Questions About Vision Loss and Other Serious Side Effects
    3. www.harmreport.com — Ozempic, Mounjaro, Trulicity - The Drugs in This Lawsuit
    4. www.harmreport.com — NAION: Symptoms, Diagnosis, Treatment and Vision Recovery
    confidence 100%

  2. GLP-1 makers Novo, Eli Lilly sued over vision loss claims

    Lawsuits against Novo Nordisk and Eli Lilly over medications including Ozempic, Wegovy, Mounjaro, and Zepbound claim these diabetes and weight-loss treatments caused permanent blindness linked to a rare optic nerve condition known as NAION. As of October 1, 2026, 247 vision-loss cases are pending in federal court. The legal actions are proceeding in two separate multidistrict litigations in Pennsylvania. No settlements have been reported yet.

    Why it matters

    These lawsuits involve allegations that GLP-1 drugs caused serious stomach injuries or sudden vision loss. The cases are being heard in two separate multidistrict litigations in Pennsylvania before Judge Karen Marston. Patients claim the medications led to permanent blindness linked to NAION. A Rutgers analysis found a small association between GLP-1 drugs and the optic-nerve condition, but noted this does not constitute proof of causation.

    What is confirmed

    • 247 vision-loss cases are pending in federal court as of October 1, 2026.
    • Lawsuits allege Ozempic, Wegovy, Mounjaro, and other GLP-1 drugs caused permanent blindness linked to NAION.
    • The legal actions are proceeding in two separate multidistrict litigations in Pennsylvania before Judge Karen Marston.
    • No settlements have been reported yet.

    Still unconfirmed

    • Trulicity lawsuits allege Eli Lilly & Company failed to warn about vision loss and stomach paralysis.

    What to watch next

    • Updates on the status of the multidistrict litigations
    • Any potential settlements or rulings from Judge Karen Marston
    • Further research on the association between GLP-1 drugs and NAION
    Sources used for this update (5)
    1. acdavislaw.com — Ozempic and Wegovy: What's next for stomach paralysis and ...
    2. healthfactsjournal.com — Ozempic Lawsuit Update: Claims, Status & Who Can File
    3. www.motleyrice.com — Zepbound® Lawsuit: Who Qualifies and Latest Health Risks
    4. www.hercasematters.com — Trulicity Lawsuit | Vision Loss, Gastroparesis & Updates
    5. www.motleyrice.com — Rybelsus® Lawsuit | GLP-1 RA Medication 2026 Legal Updates
    confidence 90%

  3. GLP-1 Makers Face Rising Vision Loss Lawsuits

    Federal court filings show 247 vision-loss cases pending as of October 1, 2026, targeting manufacturers Novo Nordisk and Eli Lilly over medications including Ozempic, Wegovy, Mounjaro, and Zepbound. Patients claim these diabetes and weight-loss treatments caused permanent blindness linked to a rare optic nerve condition known as NAION. While legal actions expand, a Rutgers analysis of adults with type 2 diabetes identified a small association between GLP-1 drugs and the optic-nerve condition, though researchers note the finding does not constitute proof of causation.

    Why it matters

    The litigation targets popular diabetes and weight-loss treatments produced by major pharmaceutical companies, focusing on severe ocular side effects such as non-arteritic anterior ischemic optic neuropathy that restricts blood flow to the optic nerve. A large United States study estimated roughly three to four additional cases of sudden vision loss for every 10,000 people treated with these medicines. Discussions surrounding the drugs also involve separate concerns regarding temporary worsening of diabetic eye disease when blood sugar drops rapidly.

    What is confirmed

    • Federal court records show 247 vision-loss cases pending against GLP-1 manufacturers as of October 1, 2026.
    • A Rutgers analysis of adults with type 2 diabetes found a small association between GLP-1 medicines and a rare optic-nerve condition, but did not establish proof of causation.
    • Researchers estimated roughly three to four additional cases of sudden vision loss for every 10,000 people treated with the medications.

    Still unconfirmed

    • Severe calorie cuts resulting from GLP-1 use may starve the brain.

    What to watch next

    • Decisions or rulings resulting from the ongoing federal litigation and expert hearings regarding GLP-1 medications.
    • Further updates on the FTC case involving Hims and Hers.
    Sources used for this update (7)
    1. peptidenewsdigest.org — GLP-1 Drugs and Your Eyes: NAION, Diabetic Retinopathy, and ...
    2. glp1newshour.substack.com — Starving Brains, Vision Loss Lawsuits and Lilly at Vogue
    3. www.glp1picks.com — Ozempic & GLP-1 Lawsuit Tracker 2026: 4,025 Cases Pending
    4. www.motleyrice.com — Tirzepatide Lawsuits: Mounjaro & Zepbound Claims Explained
    5. nowpatient.com — Vision loss warning for Ozempic Wegovy: Alert on semaglutide ...
    6. knowridge.com — Ozempic and Wegovy linked to a rare risk of sudden vision loss
    7. www.findarticles.com — Rutgers Study Links GLP-1 Drugs to Small Rise in Ischemic ...
    confidence 95%

  4. Novo Nordisk and Eli Lilly face lawsuits over GLP-1 linked vision loss

    Patients are suing Novo Nordisk and Eli Lilly after claiming GLP-1 medications caused permanent blindness and vision loss. The litigation focuses on non-arteritic anterior ischemic optic neuropathy, or NAION, which restricts blood flow to the optic nerve. Affected users of Ozempic, Wegovy, and Mounjaro are seeking compensation for these injuries. While the FDA assesses the risks, legal teams await a ruling from a September 2026 expert hearing. Some plaintiffs report total vision loss in both eyes following the use of these weight loss and diabetes treatments.

    Why it matters

    GLP-1 agonists are widely used for diabetes and weight management. The emergence of NAION as a potential side effect creates significant legal and regulatory risk for the manufacturers. These lawsuits seek to establish a causal link between the drugs and optic nerve damage.

    What is confirmed

    • Lawsuits against Novo Nordisk and Eli Lilly allege GLP-1 agonists cause NAION.
    • The litigation involves users of Ozempic, Wegovy, and Mounjaro.
    • The FDA is currently assessing the potential risks of the eye condition.

    Still unconfirmed

    • Todd Engel claims he became legally blind after using Ozempic to manage a chronic health condition.
    • Wegovy users report experiencing blurry vision linked to NAION.

    What to watch next

    • The ruling from the September 2026 expert hearing
    • FDA final assessment on GLP-1 and NAION risk
    Sources used for this update (5)
    1. www.robertkinglawfirm.com — Mounjaro Eye Side Effects Lawsuit [2026 Update] - King Law
    2. www.foxnews.com — Ozempic lawsuit claims drug caused total vision loss in both ...
    3. www.robertkinglawfirm.com — Wegovy Vision Loss Lawsuit [2026 Update] - King Law
    4. www.aol.com — Ozempic user sues company after claims his vision was ... - AOL
    5. www.drugwatch.com — Wegovy Lawsuit: October 2026 Vision Loss ... - Drugwatch
    confidence 90%

  5. GLP-1 Makers Face Lawsuits Over Vision Loss and Aging Claims

    Federal litigation against Novo Nordisk and Eli Lilly continues to mount as patients suffering from permanent vision loss seek compensation. Plaintiffs claim popular medications like Ozempic, Wegovy, and Mounjaro cause non-arteritic anterior ischemic optic neuropathy, a condition that disrupts blood flow to the optic nerve. Legal teams are awaiting a ruling following an expert hearing held in September 2026. Meanwhile, the Food and Drug Administration is assessing potential risks of the eye condition. Concurrently, drugmakers report that the treatments show signs of reducing biological aging according to molecular clocks.

    Why it matters

    The mounting legal pressure highlights the tension between blockbuster benefits and emerging safety concerns for weight-loss medications. Federal multidistrict litigation consolidates thousands of gastrointestinal injury cases alongside a growing count of vision loss claims. As legal proceedings advance, medical experts and regulators continue to debate the evidence linking the treatments to rare eye disorders.

    What is confirmed

    • Novo Nordisk and Eli Lilly face federal lawsuits alleging that GLP-1 receptor agonists cause non-arteritic anterior ischemic optic neuropathy, which results in permanent optic nerve damage and blindness.
    • A federal multidistrict litigation designated as MDL 3163 consolidates claims regarding GLP-1 vision loss.
    • The Food and Drug Administration is assessing possible non-arteritic anterior ischemic optic neuropathy risks to determine if regulatory action is necessary.
    • Drug manufacturers report that molecular aging clocks show patients taking weight-loss drugs age less quickly.

    Still unconfirmed

    • Weight-loss drugs can reverse biologic aging by two to three years.
    • Mounjaro litigation involves 4,025 gastrointestinal injury cases and 247 vision-loss cases.
    • Ellen Relkin serves as co-lead counsel in New Jersey Ozempic lawsuits regarding NAION vision loss.

    What to watch next

    • A judicial ruling following the September 2026 expert hearing
    • Regulatory decisions by the Food and Drug Administration regarding potential NAION risks
    Sources used for this update (16)
    1. peoplesjustice.info — GLP-1 Vision Loss (Ozempic / Wegovy NAION) Lawsuit Tracker
    2. peoplesjustice.info — GLP-1 Vision Loss (Ozempic / Wegovy NAION) Lawsuit
    3. www.drugwatch.com — Ozempic Lawsuit: September 2026 Blindness and Gastroparesis ...
    4. lawsuittracker.org — Ozempic Lawsuit – October 2026 Update | Lawsuit Tracker
    5. www.motleyrice.com — Ozempic® Lawsuit | September 2026 Legal Updates - Motley Rice
    6. lawsuitinformer.com — Ozempic Lawsuit Update October 2026: Waiting on a Ruling
    7. www.technologyreview.com — Weight-loss drugs show signs of slowing biological aging, say drugmakers
    8. www.drugwatch.com — I Interviewed One of the Lead Attorneys in the Ozempic Vision ...
    9. www.medscape.com — GLP-1s and NAION: Do Patients Need a Warning? - Medscape
    10. www.technologyreview.com — We’re still figuring out the side effects of GLP-1 weight-loss drugs
    11. settlementinsight.com — Mounjaro Lawsuit (Oct 2026): MDL 3094 Status, No Settlement ...
    12. theclinicaltimes.com — Patients sue GLP-1 makers over alleged vision loss and other ...
    confidence 95%

  6. Over 200 lawsuits allege GLP-1 drugs cause permanent vision loss

    Novo Nordisk and Eli Lilly face over 200 federal lawsuits alleging that GLP-1 receptor agonists, including Ozempic, Wegovy, and Mounjaro, cause non-arteritic anterior ischemic optic neuropathy (NAION). This rare condition results in permanent optic nerve damage and blindness. Plaintiffs claim the manufacturers failed to warn users of these risks. Two federal multidistrict litigations (MDLs) are currently active, with 200 vision loss cases and 3,928 gastrointestinal injury cases pending. No settlements have been reached, and the pharmaceutical companies dispute the claims.

    Why it matters

    GLP-1 drugs are widely prescribed for diabetes and weight management. These legal actions focus on whether the medications trigger an eye stroke that leads to irreversible blindness. The litigation tests the adequacy of the safety warnings provided by the manufacturers.

    What is confirmed

    • Plaintiffs allege GLP-1 drugs including Ozempic, Wegovy, and Mounjaro cause NAION, a rare form of permanent optic nerve damage.
    • Over 200 federal lawsuits have been filed regarding vision loss linked to GLP-1 medications.
    • Two federal MDLs are active with 200 vision loss cases and 3,928 GI injury cases pending.
    • Manufacturers Novo Nordisk and Eli Lilly dispute the claims of vision loss.
    • No settlement has been reached in the GLP-1 lawsuits as of September 2026.

    Still unconfirmed

    • A 59-year-old father claims Ozempic caused permanent blindness within days.

    What to watch next

    • Court rulings on the consolidation of vision loss cases into the existing MDLs
    • Public release of clinical trial data regarding NAION risks
    • Potential FDA updates to GLP-1 drug warning labels
    Sources used for this update (9)
    1. www.yahoo.com — Ozempic Vision Loss Lawsuits Allege Permanent Eye Damage - Yahoo
    2. www.lanierlawfirm.com — NAION Ozempic GLP-1 Drugs Lawsuit: September 2026 Update
    3. timesofindia.indiatimes.com — 59-year-old dad claims Ozempic left him ‘permanently blind’ within days: What we know about vision loss due to GLP-1 and the lawsuits
    4. lawcompensate.com — GLP-1 Lawsuit 2026: MDL Status, Case Counts, No Payout
    5. www.yahoo.com — Ozempic, Wegovy users sue over rare, permanent blindness - Yahoo
    6. www.cdc.gov — Think. Test. Treat TB | Think. Test. Treat TB. | CDC
    7. weightlossproviderguide.com — GLP-3 Retatrutide: Results, Side Effects & Trials
    8. www.cdc.gov — Testing and Respiratory Viruses | Respiratory Illnesses | CDC
    9. www.thetechedvocate.org — Vision Loss Nightmare: Popular Weight Loss Drugs Spark 200+ Lawsuits
    confidence 90%

  7. Patients sue Novo, Eli Lilly over vision loss linked to GLP-1 drugs

    Hundreds of patients have filed lawsuits against manufacturers of GLP-1 receptor agonists, including Ozempic, Wegovy, and Mounjaro, alleging the drugs cause sudden vision loss. The litigation targets companies like Novo Nordisk and Eli Lilly, claiming the medications increase the risk of this rare condition. Plaintiffs describe sudden blindness, characterized as an "eye stroke."

    Why it matters

    The lawsuits seek to establish a direct link between the weight-loss and diabetes medications and ocular injuries. GLP-1 receptor agonists are used to manage Type 2 diabetes and obesity. They work by activating the GLP-1 receptor, reducing blood sugar, appetite, and energy intake.

    What is confirmed

    • GLP-1 receptor agonists are a class of medications that can help manage Type 2 diabetes and obesity.
    • GLP-1 agonists work by activating the GLP-1 receptor, causing reduced blood sugar, reduced appetite, and reduced energy intake.
    • Patients who took GLP-1 drugs such as Ozempic and Wegovy are suing Novo Nordisk and Eli Lilly over sudden vision loss.

    Still unconfirmed

    • Some sources characterize the vision loss as an "eye stroke"

    What to watch next

    • The outcome of the lawsuits against Novo Nordisk and Eli Lilly
    • Further research on the link between GLP-1 drugs and vision loss
    • FDA or regulatory agency statements on GLP-1 drug safety
    Sources used for this update (7)
    1. med.stanford.edu — GLP-1s 101: What the science says about weight loss, side effects, safety
    2. en.sedaily.com — U.S. Patients Sue Drugmakers Over Vision Loss Linked to Ozempic, Wegovy
    3. my.clevelandclinic.org — GLP-1 Agonists: What They Are, How They Work & Side Effects
    4. www.webmd.com — A Guide to GLPs-1s for Weight Loss - WebMD
    5. en.wikipedia.org — Glucagon-like peptide-1 - Wikipedia
    6. en.wikipedia.org — GLP-1 receptor agonist - Wikipedia
    7. www.healthline.com — What to Know About GLP-1 Long-term Side Effects - Healthline
    confidence 90%

  8. Hundreds sue GLP-1 makers over sudden vision loss

    Hundreds of patients have filed lawsuits against manufacturers of GLP-1 receptor agonists, including Ozempic, Wegovy, and Mounjaro, alleging the drugs cause a rare form of vision loss. Plaintiffs describe sudden blindness, which some sources characterize as an "eye stroke." The litigation targets companies like Novo Nordisk and Eli Lilly, claiming the medications increase the risk of this rare condition. While individual users have shared accounts of immediate sight loss, the legal actions seek to establish a direct link between the weight-loss and diabetes medications and these ocular injuries.

    Why it matters

    GLP-1 receptor agonists are widely used for managing type 2 diabetes and obesity. These lawsuits focus on a specific, rare type of vision loss rather than common side effects. The outcome will determine if manufacturers must update warning labels regarding ocular risks.

    What is confirmed

    • Hundreds of lawsuits allege GLP-1 drugs like Ozempic, Wegovy, and Mounjaro caused vision loss.
    • Plaintiffs allege GLP-1 receptor agonists increase the risk of a rare form of vision loss.

    Still unconfirmed

    • A Massachusetts man described his sudden blindness as "Boom, lights out" after taking a GLP-1 drug.
    • The vision loss is linked to a rare condition described as an eye stroke.

    What to watch next

    • Court rulings on the admissibility of evidence linking GLP-1s to eye strokes
    • Official responses or medical data releases from Novo Nordisk and Eli Lilly
    • Regulatory reviews by the FDA regarding GLP-1 vision loss warnings
    Sources used for this update (10)
    1. Boston 25 News — ‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1
    2. USA Today — Are GLP-1s causing blindness? What we know about rare cases
    3. NewsNation — Patients sue GLP-1 makers over sudden loss of vision
    4. ABC News - Breaking News, Latest News and Videos — What GLP-1 users should know about the potential risk of a rare type of vision loss
    5. WSJ — Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss
    6. The Boston Globe — Could GLP-1s be linked to a rare type of vision loss? Here’s what to know.
    7. Fox News — Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
    8. AZ Family — Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss
    9. TODAY.com — Woman Details Losing Vision After Taking GLP-1 As Hundreds of Patients Sue Drug Companies
    10. nypost.com — GLP-1 drugs increase rare ‘eye stroke’ linked to vision loss, hundreds of lawsuits allege
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community